Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi. Aminobutane bisphosphonate inhibits proliferation of intracellular amastigote Trypanosoma cruzi and lacks activity against non-infective epimastigote forms. Aminobutane bisphosphonate reduces osteoclastic bone resorption, osteoid surface extent, and osteoclast number per mm of bone surface.Aminobutane bisphosphonate alters mineral apposition rate in intact legs, inhibits immobilization-induced bone loss, and increases trabecular bone volume in Sprague-Dawley rats. Aminobutane bisphosphonate can be used for the research of american trypanosomiasis (chagas' disease) and immobilization-related bone loss.

ALK-IN-24 is an orally active ALK inhibitor with an IC50 value of 1.7 nM. ALK-IN-24 also inhibits insulin receptor kinase with an IC50 value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer.

Alixorexton (ALKS 2680) enantiomer is the enantiomer of Alixorexton. Alixorexton is a selective, orally active and brain-penetrant agonist for orexin-2 receptor and can be used for hypersomnias research.

AldoView (Compound 3) is an intermediate. AldoView can be labeled with fluorine-18 to synthesize [18F]AldoView. [18F]AldoView is a highly selective aldosterone synthase PET imaging agent. AldoView can be used in imaging studies of primary aldosteronism.

ALC1-IN-1 (compound 1) is an ALC1 inhibitor in crystalline form that can be used in the research of cancer.

AKT1-IN-11, a Podophyllotoxin derivative, is a AKT1/tubulin dual inhibitor. AKT1-IN-11 down-regulates the phosphorylation level of AKT kinase in tumor cells, disrupting cell proliferation, causeing G2/M phase arrest and inducing apoptosis. AKT1-IN-11 also promotes tubulin depolymerization. AKT1-IN-11 can be used for the research of colorectal cancer.

AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.

AFP464 (NSC710464) is a prodrug of Aminoflavone and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 is applicable to research related to breast cancer.

Aescigenin is a triterpenoid saponin compound that can be found in Aesculus hippocastanum. Aescigenin is the main component of sodium β-aescin, a compound that has the functions of reducing tissue edema, improving microcirculation, and anti-inflammation. It can be used in research on Bell's palsy.

ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease.

ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan. Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.

Adavosertib (AZD1775; MK-1775) acid (Compound 9) is a derivative of AZD1775 and can be used for the synthesis of PROTAC.

ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions.

ACHM-025 is a prodrug, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. ACHM-025 can be used for the research of cancer, such as leukemia.

AChE-IN-98 (Compound 26) is an AChE inhitibor, with an IC50 value of 7.3 μM for ee AChE. AChE-IN-98 is also a Coumarin derivative. AChE-IN-98 can be used in the research of Alzheimer's disease.

AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease.

ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.

AAK1-IN-12 (Compound 4) is a selective, orally active AAK1 inhibitor that can cross the blood-brain barrier. AAK1-IN-12 is applicable to the research of schizophrenia, Parkinson's disease, neuropathic pain and Alzheimer's disease.

8-Aminoguanosine is a purine nucleoside phosphorylase inhibitor. 8-Aminoguanosine blocks purine nucleoside phosphorylation via specific binding.

7.9 MAG is a non-monoolein lipid and acts as a detergent for crystallization.

6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a Ki of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression.

6ECA is a selective TGR5 receptor activator with an EC50 of 3.44 μM. 6ECA shows no significant activity at FXR. 6ECA can be used for the study of diabesity.

6-Amino-1-hexanethiol hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

5β-Cholanic acid-3,6-dione (3,6-Diketo-LCA) is a similar substance to Lithocholic acid (LCA). 5β-Cholanic acid-3,6-dione cannot activate the Vitamin D receptor (VDR), and can be used as a negative control for studying the relationship between LCA derivatives and VDR.

5-HT7R antagonist 5 (Compound (R)-4) is a 5-HT7AR antagonist, with a Ki of 46.4 nM. 5-HT7R antagonist 5 shows anticancer effects against prostate cancer.

5-HT2A&5-HT2C agonist-3 (compound 4e) is an orally bioavailable and blood-brain barrier penetrant agonist of 5-HT2A and 5-HT2C. 5-HT2A&5-HT2C agonist-3 increases intracellular calcium levels in cells overexpressing 5-HT2A or 5-HT2C receptors, and shows no activity against 5-HT2B receptors. 5-HT2A&5-HT2C agonist-3 can be used for the research of neuropsychiatric disorders.

5-Amino-2'-deoxyuridine is a thymidine analogue and substrate for chemical reaction. 5-Amino-2'-deoxyuridine can be use in the preparation of labeled probes for DNA microarray analysis.

4-Bromoisophthalic acid (4-Bromo-1,3-benzenedicarboxylic acid) is a metal-organic framework (MOF).

3'-O-(2-Nitrobenzyl)-dCTP is a reversible terminator. 3'-O-(2-Nitrobenzyl)-dCTP can be recognized and incorporated by polymerases, thereby temporarily terminating primer extension during DNA synthesis. After incorporation into the extending DNA strand, 3'-O-(2-Nitrobenzyl)-dCTP temporarily halts the DNA polymerase extension reaction, and its 3'-O-(2-nitrobenzyl) blocking group can be removed by laser irradiation to regenerate a free 3'-OH for subsequent primer extension cycles. 3'-O-(2-Nitrobenzyl)-dCTP is applicable for resolving homopolymeric regions in DNA templates.

3-Benzylmalic acid (3-Benzylmalate) can be converted from 2-Benzylmalic acid through a HphCD-mediated hydroxyl isomerization reaction.